Molecular Diagnostics

Global Molecular Diagnostics Market to Reach US$27.0 Billion by 2030

The global market for Molecular Diagnostics estimated at US$16.0 Billion in the year 2024, is expected to reach US$27.0 Billion by 2030, growing at a CAGR of 9.2% over the analysis period 2024-2030. Reagents & Kits, one of the segments analyzed in the report, is expected to record a 9.7% CAGR and reach US$16.0 Billion by the end of the analysis period. Growth in the Instruments segment is estimated at 8.2% CAGR over the analysis period.

The U.S. Market is Estimated at US$6.8 Billion While China is Forecast to Grow at 10.5% CAGR

The Molecular Diagnostics market in the U.S. is estimated at US$6.8 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 10.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 8.6% and 7.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 8.4% CAGR.

Global Molecular Diagnostics Market - Key Trends & Drivers Summarized

What Is Molecular Diagnostics and Why Does It Matter?

Molecular diagnostics is a collection of techniques used to analyze biological markers in the genome and proteome—the individual`s genetic code and how their cells express their genes as proteins—by applying molecular biology to medical testing. The field has grown significantly with advancements in genomic and proteomic technology, which have revolutionized how diseases are detected, diagnosed, and managed. Molecular diagnostics involves tests that can detect specific sequences in DNA or RNA that may or may not be associated with disease. Tests are often utilized to diagnose infectious diseases, understand a patient’s predisposition to a disease, identify DNA markers for the early detection of cancer, or detect genetic mutations that can drive more personalized treatments. This form of diagnostics is particularly renowned for its ability to rapidly identify and respond to pathogens and mutations, offering the potential for earlier intervention than traditional methods.

How Are Technological Advancements Shaping Molecular Diagnostics?

The technological landscape of molecular diagnostics is rapidly evolving, driven by leaps in areas such as gene sequencing and high-throughput methodologies. Next-generation sequencing (NGS) technologies allow for the simultaneous and rapid sequencing of millions of DNA molecules, greatly reducing the cost and increasing the speed of genetic analysis. This capability is crucial for the development of personalized medicine, where treatments can be tailored to the genetic profiles of individual patients. Additionally, improvements in data analysis tools and bioinformatics support the interpretation of vast amounts of genetic data, turning raw data into actionable medical insights. Digital PCR and CRISPR-based diagnostics are other innovations enhancing the precision and efficiency of molecular tests, allowing for the detection of low-abundance biomarkers and providing high levels of accuracy.

What Are the Key Applications and Implications in Healthcare?

Molecular diagnostics plays a pivotal role in several areas of healthcare, influencing everything from cancer screening to the management of infectious diseases and chronic conditions. In oncology, molecular tests help identify specific biomarkers that guide the use of targeted therapies. For infectious diseases, these diagnostics provide the ability to quickly identify pathogens and their resistance profiles, which is essential for effective treatment and control measures. Furthermore, molecular diagnostics is integral to the advancements in pharmacogenomics, where genetic information is used to predict patient responses to drugs, thereby improving safety and efficacy. The ability to monitor disease progression and response to treatment in real time is another area where molecular diagnostics is becoming indispensable, offering new tools for doctors to manage diseases more effectively.

What Drives the Growth of the Molecular Diagnostics Market?

The growth in the molecular diagnostics market is driven by several factors, including technological advancements, increasing prevalence of infectious diseases and cancer, rising demand for personalized medicine, and greater health awareness among consumers. The integration of high-throughput sequencing technologies has dramatically increased the capability and affordability of genetic testing, making it accessible to a broader population. This accessibility is crucial for the early detection of diseases and for tailoring specific therapies to individuals, which is at the heart of personalized medicine. Additionally, the global rise in health consciousness and preventive healthcare measures has heightened demand for these diagnostics. Governments and healthcare institutions are also recognizing the value of molecular diagnostics in improving health outcomes, leading to greater investment in this technology. Moreover, the ongoing development of more sophisticated data analysis tools has enabled the extraction of more detailed insights from genetic data, further propelling the market forward. These factors collectively ensure sustained growth and continual innovation within the field of molecular diagnostics.

SCOPE OF STUDY:

The report analyzes the Molecular Diagnostics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Component (Reagents & Kits, Instruments, Software & Service); Technology (PCR, In-Situ Hybridization, Isothermal Amplification, Sequencing, Chips & Microarrays, Other Technologies); Application (Infectious Disease, Oncology Testing, Genetic Testing, Other Applications)

Geographic Regions/Countries:
World; USA; Canada; Japan; China; Europe; France; Germany; Italy; UK; Spain; Russia; Rest of Europe; Asia-Pacific; Australia; India; South Korea; Rest of Asia-Pacific; Latin America; Argentina; Brazil; Mexico; Rest of Latin America; Middle East; Iran; Israel; Saudi Arabia; UAE; Rest of Middle East; Africa.

Select Competitors (Total 84 Featured) -

• Abbott Laboratories, Inc.
• Agilent Technologies, Inc.
• Becton, Dickinson and Company
• Beckman Coulter, Inc.
• Asuragen, Inc.
• Analytik Jena AG
• A. Menarini Diagnostics Srl
• Abaxis, Inc.
• Agena Bioscience, Inc.
• Advanced Cell Diagnostics, Inc.
• AutoGenomics, Inc.
• Akonni Biosystems, Inc.
• Berg LLC
• Agendia, Inc.
• BioAgilytix Labs

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.